Rgenix Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $40M
Latest Deal Amount
  • Investors
  • 14

Rgenix General Information

Description

Developer of novel cancer drugs that target key pathways in cancer progression. The company's drugs identify novel cancer targets that drive tumor growth and cancer progression using a microRNA based target discovery platform and treats it via a oral small molecule cancer metabolism inhibitor, enabling cancer patients to get optimal cure using drugs that target using small molecules and antibodies.

Contact Information

Website
www.rgenix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 310 East 67th Street
  • Suite 1-12
  • New York, NY 10065
  • United States
+1 (646) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rgenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 09-Oct-2018 $40M 000.00 00000 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 03-Jun-2016 0000 000.00 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 31-Jul-2015 000 000.00 000.00 Completed Pre-Clinical Trials
2. Grant 11-Aug-2014 $200K $2.5M Completed Pre-Clinical Trials
1. Seed Round 30-Sep-2013 $2.5M $2.5M 000.00 Completed Pre-Clinical Trials
To view Rgenix’s complete valuation and funding history, request access »

Rgenix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 13,889,841 $0.000100 $0.61 $0.61 1x $0.61 6.77%
Seed 5,869,618 $0.000100 $0.53 $0.53 1x $0.53 3.1%
To view Rgenix’s complete cap table history, request access »

Rgenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel cancer drugs that target key pathways in cancer progression. The company's drugs identify novel cance
Drug Discovery
New York, NY
11 As of 2017
000.00
0000 0000-00-00
00000000000 000.00

0000 000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000000000000
Culver City, CA
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rgenix Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000 000000000000 Venture Capital-Backed Boston, MA 00 000.00 0000000000 0 000.00
You’re viewing 5 of 23 competitors. Get the full list »

Rgenix Executive Team (14)

Name Title Board Seat Contact Info
Masoud Tavazoie Ph.D Co-Founder, Board Member and Chief Executive Officer
Sohail Tavazoie Ph.D Co-Founder, Scientific & Clinical Advisor
Michael Szarek Ph.D Vice President, Clinical & Regulatory Affairs
Foster Gonsalves Ph.D Vice President, Drug Development & Strategy
Steven Wald Vice President of Chemistry & Pharmaceutical Sciences
You’re viewing 5 of 14 executive team members. Get the full list »

Rgenix Board Members (11)

Name Representing Role Since
Antoine Papiernik Sofinnova Partners Board Member 000 0000
David Darst Self Chief Operating Officer & Board Observer 000 0000
Eric Rowinsky MD Self Board Member & Executive Chairman 000 0000
Jue Pu Rgenix Board Member 000 0000
Masoud Tavazoie Ph.D Rgenix Co-Founder, Board Member and Chief Executive Officer 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Rgenix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rgenix Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bolur Holdings Impact Investing Minority 000 0000 000000 0
EXOR Seeds Venture Capital Minority 000 0000 000000 0
Lepu Medical Corporation Minority 000 0000 000000 0
Oceanpine Capital Venture Capital Minority 000 0000 000000 0
Oceanpine Healthcare Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial